Peptide Research Landscape 2026: The Year's Major Trials
TL;DR: The past year in peptide research was defined by the incretin class: SURMOUNT-5 delivered the first large head-to-head of tirzepatide vs semaglutide, the triple agonist retatrutide advanced through Phase 3 TRIUMPH, and the dual GLP-1/glucagon agonist survodutide drew growing attention. A summary of published research, not therapeutic claims.
The 2026 picture in one paragraph
The past twelve months in peptide research were defined by the incretin-receptor class. The headline event was SURMOUNT-5, the first large randomised head-to-head of tirzepatide against semaglutide, which moved the conversation from "does this class work" to "which agonist design works best". Alongside it, the triple agonist retatrutide continued through its Phase 3 TRIUMPH programme, and a newer dual GLP-1/glucagon agonist, survodutide, drew growing early interest. Outside metabolism, repair, cognitive, growth-axis and longevity peptides continued to be studied largely in preclinical and early-clinical settings. This page summarises the year and links to a full research summary for every compound we cover.
Use it as a map: each compound and comparison below links to a dedicated, citation-backed summary. Everything here is framed for research reference only.
Metabolic & incretin-receptor research
This was the class that dominated 2026. Three threads mattered most: a definitive head-to-head, a maturing triple agonist, and an emerging dual agonist.
For mechanism context, see Is retatrutide a GLP-1? and the comparison set: retatrutide vs tirzepatide vs semaglutide, vs Wegovy, and vs Ozempic. Other metabolic compounds under continued study include MOTS-c and tesamorelin.
Beyond metabolism: repair, cognitive, growth & longevity
The non-metabolic classes saw steadier, mostly preclinical activity over the year — incremental rather than headline-grabbing, but the foundation of ongoing research interest.
Repair & recovery
BPC-157 and TB-500 remained the most-studied tissue-repair research peptides, frequently examined together (see BPC-157 vs TB-500). KPV continued to be studied in inflammatory-pathway models, and GHK-Cu in dermal and remodelling research (see GHK-Cu vs BPC-157).
Cognitive & neuro
Semax and Selank remained the headline neuropeptides for BDNF and anxiolytic-pathway research (see Semax vs Selank), with DSIP studied in sleep-architecture models (see Selank vs DSIP).
Growth axis
Growth-hormone-axis research continued around CJC-1295, Ipamorelin and Tesamorelin (see CJC-1295 vs Tesamorelin).
Longevity & antioxidant
NAD+, Glutathione and Epitalon continued to feature in cellular ageing, redox and telomere-related research models.
Year at a glance
| Theme | Class | Why it mattered in 2026 |
|---|---|---|
| SURMOUNT-5 | Incretin (GIP/GLP-1 vs GLP-1) | First major head-to-head; tirzepatide reported superior to semaglutide for weight reduction |
| Retatrutide TRIUMPH | Triple agonist | Phase 3 progression of the most-watched triple-receptor design |
| Survodutide SYNCHRONIZE-1 | GLP-1 / glucagon dual | Phase 3 read-out: 16.6% weight loss at 76 weeks; MASH trials ongoing |
| Orforglipron (Foundayo) | Oral non-peptide GLP-1 | FDA approved Apr 2026 — first oral small-molecule GLP-1 for weight management |
| Oral semaglutide MHRA | Oral peptide GLP-1 | Wegovy tablet approved in UK Jun 2026 — first oral GLP-1 in Europe |
| Repair peptides | BPC-157 / TB-500 | Continued preclinical tissue-repair research; frequently studied in combination |
| Neuropeptides | Semax / Selank / DSIP | Ongoing BDNF, anxiolytic-pathway and sleep-architecture research |
| Longevity | NAD+ / Glutathione / Epitalon | Sustained interest in redox and cellular-ageing research models |
Every compound research summary
Dedicated, citation-backed research summaries for each compound we cover:
Metabolic→ Survodutide
Metabolic · new→ Tirzepatide
Metabolic→ MOTS-c
Metabolic→ BPC-157
Repair→ TB-500
Repair→ KPV
Repair · immune→ GHK-Cu
Dermal · antioxidant→ Semax
Cognitive→ Selank
Cognitive→ DSIP
Cognitive · sleep→ CJC-1295
Growth→ Ipamorelin
Growth→ Tesamorelin
Growth · metabolic→ NAD+
Longevity→ Glutathione
Antioxidant→ Epitalon
Longevity→ Melanotan II
Melanocortin→
Head-to-head comparisons
Side-by-side research comparisons across the most-searched matchups:
Comparison · 2026→ Retatrutide vs Tirzepatide vs Semaglutide
Comparison→ Retatrutide vs Wegovy
Comparison→ Retatrutide vs Ozempic
Comparison→ BPC-157 vs TB-500
Comparison→ GHK-Cu vs BPC-157
Comparison→ Semax vs Selank
Comparison→ Selank vs DSIP
Comparison→ CJC-1295 vs Tesamorelin
Comparison→
Prefer to build your own? The comparison tool lets you put up to five research compounds side by side on mechanism, receptors, molecular weight and more.
Frequently Asked Questions
What were the biggest peptide research stories of 2026?
The incretin-receptor class dominated: the SURMOUNT-5 head-to-head of tirzepatide versus semaglutide, continued readouts from retatrutide's TRIUMPH Phase 3 programme, and growing early interest in survodutide. Repair, cognitive, growth-axis and longevity peptides continued to be studied largely in preclinical and early-clinical settings. Summarised here for research reference only.
What is SURMOUNT-5?
A randomised clinical trial that directly compared tirzepatide with semaglutide for body-weight reduction — the first major head-to-head between the two. As reported, tirzepatide produced a greater mean weight reduction. See our dedicated SURMOUNT-5 summary.
Are any of these compounds approved for human use?
Approval status varies by compound and jurisdiction, and several remain investigational. Velox Peptides supplies compounds strictly for in vitro research use only. Nothing on this page is a therapeutic claim or endorsement.
